ESG

A first-in-class antibody shows a strong safety profile, de-risking development and offering a new, targeted approach for severe autoimmune diseases.

Alerus Financial is set to release its Q4 results, capping a year of strategic growth. Investors watch to see if its unique model can sustain momentum.

CES 2026 opens with AI dominating everything from PCs to factories, while Las Vegas reaps the rewards of a massive convention center overhaul.

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

The water technology giant's acquisition of Leonard Valve signals a major strategic pivot into digital water management for critical commercial markets.

With a $30.9M rights offering, Rare Element Resources aims to advance its Wyoming project, a key piece in America's race for rare earth independence.

A new $65 million facility for a top U.S. intelligence lab cements Maryland's role as a national security research powerhouse. Here's what it means.

LifeVantage heads to the ICR Conference to woo investors. Can its cellular health science overcome market headwinds and a volatile direct selling landscape?

Chemelex's buyout of EHT Group integrates the SmartTrace platform, signaling a major shift toward AI-driven predictive maintenance in industrial heat tracing.

Dutch tech firm Aquablu unveils its BOLD system at CES, using AI and wearable data to deliver personalized, sustainable hydration to US offices and gyms.

The first-ever Wegovy pill is here. Digital health firm eMed is partnering with Novo Nordisk to offer it, promising a new era of guided, responsible care.

UBC's strategic buyout of AI-specialist Evidinno signals a major shift in evidence generation, promising faster, smarter data solutions for biopharma.

By blending AI innovation with a 'whole person' wellness philosophy, MERGE sets a new standard for employee experience and industry leadership.

With its lead asset TEC-001 targeting tough liver cancers, Teclison's presence at the ASCO GI Symposium puts its innovative approach in the spotlight.

With a new CEO who has three FDA-approved drugs to his name, Catalio-backed Rhapsogen is poised to redefine autoimmune disease treatment. Here's why.

EdgeCortix's SAKURA-II processor survives brutal radiation tests, paving the way for intelligent, real-time decision-making on satellites and the Moon.

A new 'RaiseWell Certified' label for beef just launched, promising total traceability and higher ethical standards. But will it finally clear up consumer confusion?

A groundbreaking Duke trial combines a novel device to lure cancer cells with targeted immunotherapy, offering real-time tracking and new hope for patients.

An Indianapolis firm's major investment boosts domestic battery manufacturing, aiming to secure the supply chain for critical military and drone technology.

Following its acquisition of Stryker's spine assets, VB Spine's purchase of a key French facility signals a major disruption in the competitive medtech landscape.